ES2279585T3 - Polipeptido coestimulante de celulas t, anticuerpos monoclonales, su preparacion y su uso. - Google Patents

Polipeptido coestimulante de celulas t, anticuerpos monoclonales, su preparacion y su uso. Download PDF

Info

Publication number
ES2279585T3
ES2279585T3 ES98956800T ES98956800T ES2279585T3 ES 2279585 T3 ES2279585 T3 ES 2279585T3 ES 98956800 T ES98956800 T ES 98956800T ES 98956800 T ES98956800 T ES 98956800T ES 2279585 T3 ES2279585 T3 ES 2279585T3
Authority
ES
Spain
Prior art keywords
cells
lymphocytes
molecule
kda
activated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98956800T
Other languages
English (en)
Spanish (es)
Inventor
Richard Kroczek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BUNDESREPUBLIK DEUTSCHLAND LET
Robert Koch Institute
Original Assignee
BUNDESREPUBLIK DEUTSCHLAND LET
Robert Koch Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26040229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2279585(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19821060A external-priority patent/DE19821060A1/de
Application filed by BUNDESREPUBLIK DEUTSCHLAND LET, Robert Koch Institute filed Critical BUNDESREPUBLIK DEUTSCHLAND LET
Application granted granted Critical
Publication of ES2279585T3 publication Critical patent/ES2279585T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES98956800T 1997-09-23 1998-09-23 Polipeptido coestimulante de celulas t, anticuerpos monoclonales, su preparacion y su uso. Expired - Lifetime ES2279585T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19741929 1997-09-23
DE19741929 1997-09-23
DE19821060A DE19821060A1 (de) 1997-09-23 1998-05-11 Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
DE19821060 1998-05-11

Publications (1)

Publication Number Publication Date
ES2279585T3 true ES2279585T3 (es) 2007-08-16

Family

ID=26040229

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98956800T Expired - Lifetime ES2279585T3 (es) 1997-09-23 1998-09-23 Polipeptido coestimulante de celulas t, anticuerpos monoclonales, su preparacion y su uso.

Country Status (8)

Country Link
US (2) US7259247B1 (https=)
EP (1) EP1017723B1 (https=)
JP (1) JP4463418B2 (https=)
AU (1) AU752433B2 (https=)
CA (1) CA2305350C (https=)
DE (1) DE59813875D1 (https=)
ES (1) ES2279585T3 (https=)
WO (1) WO1999015553A2 (https=)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US7259247B1 (en) 1997-09-23 2007-08-21 Bundersrespublik Deutschaland Letztvertreten Durch Den Direktor Des Robert-Koch-Institutes Anti-human T-cell costimulating polypeptide monoclonal antibodies
DE19821060A1 (de) 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
WO2000019988A1 (en) * 1998-10-07 2000-04-13 Millennium Pharmaceuticals, Inc. NOVEL Th2-SPECIFIC MOLECULES AND USES THEREOF
US8624010B1 (en) 1999-02-03 2014-01-07 Steven K. Yoshinaga Nucleic acids encoding B7RP1
US7708993B2 (en) 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
DK1149114T3 (da) 1999-02-03 2014-06-23 Amgen Inc Polypeptider, der er involveret ved et immunrespons
US7435796B1 (en) 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
AU6458400A (en) * 1999-08-11 2001-03-13 Isis Innovation Limited Nucleic acid, polypeptides, assays, therapeutic methods and means
JP4210454B2 (ja) * 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP3871503B2 (ja) * 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
PT1218504E (pt) * 1999-09-21 2007-10-22 Genetics Inst Llc Novas moléculas gl50 e suas utilizações
EP1900816A3 (en) * 1999-09-21 2008-03-26 Genetics Institute, LLC GL50 molecules and uses therefor
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
AU1796902A (en) * 2000-11-28 2002-06-11 Amgen Inc Novel polypeptides involved in immune response
AU2002308267A1 (en) * 2001-01-16 2002-10-03 Bayer Aktiengesellschaft Regulation of human icos v protein
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
AU2005235718B2 (en) 2004-04-23 2011-09-22 Bundesrepublik Deutschland Letztvertreten Durch Das Robert-Koch-Institut Vertreten Durch Seinen Prasidenten Method for the treatment of T cell mediated conditions by depletion of icos-positive cells in vivo
US9244059B2 (en) 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
ES2635335T3 (es) 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
ES2612914T3 (es) 2011-03-31 2017-05-19 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos dirigidos contra Icos y usos de los mismos
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
EA037554B1 (ru) 2013-03-15 2021-04-13 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Анти-lag-3 связывающие белки
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
TWI719970B (zh) 2015-03-23 2021-03-01 美商永斯醫療股份有限公司 針對ｉｃｏｓ之抗體
KR20250073532A (ko) 2015-09-02 2025-05-27 이뮤텝 에스.에이.에스. 항-lag-3 항체
EP3365372A1 (en) 2015-10-22 2018-08-29 Jounce Therapeutics, Inc. Gene signatures for determining icos expression
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
KR20260030924A (ko) 2016-08-09 2026-03-06 키맵 리미티드 항-icos 항체
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
PE20210665A1 (es) 2018-03-23 2021-03-31 Bristol Myers Squibb Co Anticuerpos contra mica y/o micb y sus usos
EP3977132A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Cell localization signature and combination therapy
JP2022534967A (ja) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 多腫瘍遺伝子シグネチャーおよびその使用
KR20220016155A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
LT4051708T (lt) 2019-10-28 2025-04-10 Medimmune Limited Užkrūčio liaukos stromos limfopoetiną (tslp) surišančių antikūnų sausų miltelių pavidalo vaisto formos ir jų panaudojimo būdai
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
AU2021334361A1 (en) 2020-08-31 2023-05-11 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
JP2024501029A (ja) 2020-12-28 2024-01-10 ブリストル－マイヤーズ スクイブ カンパニー Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
SMT202500208T1 (it) 2020-12-28 2025-07-22 Bristol Myers Squibb Co Composizioni anticorpali e metodi per il loro uso
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
US20220396623A1 (en) 2021-05-18 2022-12-15 Kymab Limited Uses of anti-icos antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
EP4493575A1 (en) 2022-03-18 2025-01-22 Bristol-Myers Squibb Company Methods of isolating polypeptides
US20250340641A1 (en) 2022-05-18 2025-11-06 Kymab Limited Uses of anti-icos antibodies
EP4531916A1 (en) 2022-06-02 2025-04-09 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2024054992A1 (en) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Methods of separating chelator
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
CN121712571A (zh) 2023-08-15 2026-03-20 百时美施贵宝公司 陶瓷羟基磷灰石色谱流通法
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8801537D0 (sv) 1988-04-26 1988-04-26 Ellco Food Ab Cellodlingsmedium samt forfarande for dess framstellning
KR900702370A (ko) 1988-10-06 1990-12-06 제임스 디. 그랜트 가용성 t세포 표면분자를 사용하는 치료 및 진단방법
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US7112655B1 (en) * 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
DE19821060A1 (de) * 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
US7259247B1 (en) 1997-09-23 2007-08-21 Bundersrespublik Deutschaland Letztvertreten Durch Den Direktor Des Robert-Koch-Institutes Anti-human T-cell costimulating polypeptide monoclonal antibodies

Also Published As

Publication number Publication date
EP1017723A2 (de) 2000-07-12
EP1017723B1 (de) 2007-01-10
JP4463418B2 (ja) 2010-05-19
AU1332099A (en) 1999-04-12
WO1999015553A3 (de) 1999-05-20
US7259247B1 (en) 2007-08-21
AU752433B2 (en) 2002-09-19
WO1999015553A2 (de) 1999-04-01
US20080118513A1 (en) 2008-05-22
CA2305350C (en) 2015-04-07
CA2305350A1 (en) 1999-04-01
DE59813875D1 (de) 2007-02-22
JP2001517425A (ja) 2001-10-09

Similar Documents

Publication Publication Date Title
ES2279585T3 (es) Polipeptido coestimulante de celulas t, anticuerpos monoclonales, su preparacion y su uso.
JP5021008B2 (ja) Ｔ細胞共同刺激性ポリペプチド、モノクローナル抗体、ならびにその製法および使用
KR100609444B1 (ko) 이식편 거절반응 억제제
KR101564713B1 (ko) Ｎｋｇ2ａ에 대한 단클론 항체
JP4716350B2 (ja) 潜伏期膜タンパク質に対する抗体およびそれらの使用
Liu et al. Mechanism of antigen-driven selection in germinal centres
Guy-Grand et al. Two gut intraepithelial CD8+ lymphocyte populations with different T cell receptors: a role for the gut epithelium in T cell differentiation.
ES2149149T3 (es) Proteinas de union a interleuquina-18, su preparacion y uso.
RU2369636C2 (ru) Лиганд gitr и связанные с лигандом gitr молекулы и антитела и варианты их применения
KR100834809B1 (ko) Ｂａｆｆ, 관련 차단제 및 면역 반응에서 ｂ 세포와면역글로불린을 촉진 및 억제하는데에 있어서 이들의 용도
Gravestein et al. Cloning and expression of murine CD27: comparison with 4‐1BB, another lymphocyte‐specific member of the nerve growth factor receptor family
ES2321687T3 (es) Receptor activador implicado en la citotoxicidad natural mediada por las celulas destructoras naturales humanas y anticuerpos que identifican dicho receptor.
JP4768193B2 (ja) ヒトｌｄｌ受容体に対するモノクローナル抗体、その産生および用途
AU2002323894B2 (en) Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use
JP2007537691A (ja) 免疫不全の治療のための新規組成物と方法
Williams et al. Immunotherapeutic strategies targeting rheumatoid synovial T-cell receptors by DNA inoculation
KR100301796B1 (ko) 면역억제능이 있는 항-씨디40 리간드 모노클로날 항체
JP2005507236A (ja) 抗原性ポリペプチドに結合する新規抗体、抗原をコードする核酸、および使用方法
Ossendorp et al. Cloning and expression of murine CD27: comparison with 4-1BB, another lymphocyte-specific member of the nerve growth factor receptor family